Benefect Botanical Disinfectants & Cleaners for the Insurance Restoration Industry

News


Does Benefect Kill Ebola?
posted on October 16, 2014 4:00 PM
http://www.benefect.com/docs/Does Benefect Kill Ebola_USA.pdf

Ebola is a contagious deadly disease found primarily in Africa but isolated cases have recently been revealed in North America. Ebola is still expected to be a controllable public threat in North America where hygiene standards & health care systems are more advanced. The Ebola virus is an Enveloped Virus which is transmitted through direct contact with infected blood or body fluids/substances.

Although neither Benefect nor any other disinfectant have been specifically tested against Ebola, based on the CDC disinfectant recommendations per Ebola (below) & their rankings of disinfectant potency (See chart in the link above), Benefect Decon 30 Disinfectant has efficacy against common Non-Enveloped Viruses such as Rhinovirus plus common Enveloped Viruses such as Influenza, H1N1. Benefect Broad Spectrum Disinfectant is an Intermediate-Level Tuberculocidal Hospital Disinfectant which is considerably more potent than what is normally required for an Enveloped Virus such as Ebola & has additional efficacy against the common Non-Enveloped Virus HIV.

The CDC specifically states that “although there are no products with specific label claims against the Ebola virus, enveloped viruses such as Ebola are susceptible to a broad range of hospital disinfectants used to disinfect hard, non-porous surfaces. In contrast, Non-Enveloped Viruses are more resistant to disinfectants. As a precaution, selection of a disinfectant product with a higher potency than what is normally required for an Enveloped Virus is being recommended at this time.”

(http://www.cdc.gov/vhf/ebola/hcp/environmental-infection-control-in-hospitals.html)

The EPA has not released any official guidance regarding Ebola claims for EPA Registered Disinfectant Manufacturers as of the date of this release. We are assured that they are working 24/7 reviewing their standards to come up with a surrogate claim for the marketplace during this time as they have done for H1N1 & SARS in the past.













Note: this is a semblance of publicly available interim guidance which is subject to change. Proper due diligence is advised.


< back to News page